Recursion Pharmaceuticals Inc (RXRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Recursion Pharmaceuticals Inc (RXRX) has a cash flow conversion efficiency ratio of -0.079x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-81.10 Million) by net assets ($1.02 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check how strategically is Recursion Pharmaceuticals Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Recursion Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Recursion Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See Recursion Pharmaceuticals Inc book value and equity for net asset value and shareholders' equity analysis.
Recursion Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Recursion Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Corporate Travel Management Ltd
AU:CTD
|
0.010x |
|
Robertet SA
PA:RBT
|
0.130x |
|
Zhejiang Fulai New Material Co.Ltd.
SHG:605488
|
0.025x |
|
Personal Assets Trust plc
LSE:PNL
|
-0.015x |
|
Sionna Therapeutics, Inc. Common Stock
NASDAQ:SION
|
-0.054x |
|
Novavax Inc
NASDAQ:NVAX
|
0.224x |
|
Zhuzhou Times New Material Technology Co Ltd
SHG:600458
|
-0.051x |
|
Faraday Technology Corp
TW:3035
|
-0.038x |
Annual Cash Flow Conversion Efficiency for Recursion Pharmaceuticals Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Recursion Pharmaceuticals Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Recursion Pharmaceuticals Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.13 Billion | $-371.81 Million | -0.329x | +5.28% |
| 2024-12-31 | $1.03 Billion | $-359.17 Million | -0.347x | +44.10% |
| 2023-12-31 | $463.44 Million | $-287.78 Million | -0.621x | -261.18% |
| 2022-12-31 | $485.81 Million | $-83.52 Million | -0.172x | +41.15% |
| 2021-12-31 | $542.94 Million | $-158.61 Million | -0.292x | -232.75% |
| 2020-12-31 | $-206.29 Million | $-45.40 Million | 0.220x | -52.06% |
| 2019-12-31 | $-124.27 Million | $-57.04 Million | 0.459x | -- |
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenom… Read more